PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Aprea Therapeutics
Start Date
November 30, 2017
End Date
August 16, 2018
Administered By
Duke Cancer Institute
Awarded By
Aprea Therapeutics
Start Date
November 30, 2017
End Date
August 16, 2018